Ovid Therapeutics (OVID) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.15, -4.87% vs the prior close of $2.26.
- Volume 1.33M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
OVID slides 4.9% to $2.15, a 6-month low. Closed at $2.15, -4.87% vs the prior close of $2.26. Day range $2.11–$2.30, opened at $2.26.
OVID daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — OVID slides 4.9% to $2.15, a 6-month low
- Closed at $2.15, -4.87% vs the prior close of $2.26. Day range $2.11–$2.30, opened at $2.26.
- Volume was 1.33M shares, 0.8x its 50-day average of 1.57M.
- Price is -17.9% vs its 50-day average ($2.62) and -7.7% vs its 200-day average ($2.33).
- 52-week range $1.18–$3.11; today's close sits at 50% of that range, 30.8% below the 52-week high.
Oct 15, 2026 — OVID jumps 3.2% to $2.26
- Closed at $2.26, +3.20% vs the prior close of $2.19. Day range $2.19–$2.31, opened at $2.21.
- Volume was 1.33M shares, 0.8x its 50-day average of 1.59M.
- Price is -14.0% vs its 50-day average ($2.63) and -2.9% vs its 200-day average ($2.33).
- 52-week range $1.18–$3.11; today's close sits at 56% of that range, 27.2% below the 52-week high.
Oct 14, 2026 — OVID ends flat (+0.0%) to $2.19, 3 down days in a row
- Closed at $2.19, +0.00% vs the prior close of $2.19. Day range $2.09–$2.26, opened at $2.18.
- Volume was 1.64M shares, 1.0x its 50-day average of 1.59M.
- Price is -16.9% vs its 50-day average ($2.64) and -5.8% vs its 200-day average ($2.32).
- 52-week range $1.18–$3.11; today's close sits at 52% of that range, 29.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — OVID slides 9.1% to $2.19, a 6-month low
- Closed at $2.19, -9.13% vs the prior close of $2.41. Day range $2.18–$2.41, opened at $2.41.
- Volume was 1.64M shares, 1.0x its 50-day average of 1.59M.
- Price is -17.1% vs its 50-day average ($2.64) and -5.7% vs its 200-day average ($2.32).
- 52-week range $1.18–$3.11; today's close sits at 52% of that range, 29.5% below the 52-week high.
Oct 12, 2026 — OVID dips 2.0% to $2.41
- Closed at $2.41, -2.03% vs the prior close of $2.46. Day range $2.39–$2.49, opened at $2.45.
- Volume was 876.00K shares, 0.5x its 50-day average of 1.61M — lighter than usual.
- Price is -8.9% vs its 50-day average ($2.65) and +3.9% vs its 200-day average ($2.32).
- 52-week range $1.18–$3.11; today's close sits at 64% of that range, 22.4% below the 52-week high.
Oct 9, 2026 — OVID jumps 5.1% to $2.46
- Closed at $2.46, +5.13% vs the prior close of $2.34. Day range $2.33–$2.47, opened at $2.37.
- Volume was 1.41M shares, 0.9x its 50-day average of 1.60M.
- Price is -6.9% vs its 50-day average ($2.64) and +6.2% vs its 200-day average ($2.32).
- 52-week range $1.18–$3.11; today's close sits at 66% of that range, 20.8% below the 52-week high.
Oct 8, 2026 — OVID dips 0.8% to $2.34
- Closed at $2.34, -0.85% vs the prior close of $2.36. Day range $2.29–$2.36, opened at $2.32.
- Volume was 1.65M shares, 1.0x its 50-day average of 1.58M.
- Price is -11.4% vs its 50-day average ($2.64) and +1.1% vs its 200-day average ($2.31).
- 52-week range $1.18–$3.11; today's close sits at 60% of that range, 24.6% below the 52-week high.
Oct 7, 2026 — OVID dips 0.4% to $2.36
- Closed at $2.36, -0.42% vs the prior close of $2.37. Day range $2.34–$2.46, opened at $2.36.
- Volume was 1.00M shares, 0.6x its 50-day average of 1.59M.
- Price is -10.6% vs its 50-day average ($2.64) and +2.2% vs its 200-day average ($2.31).
- 52-week range $1.18–$3.11; today's close sits at 61% of that range, 24.0% below the 52-week high.
Oct 6, 2026 — OVID rises 1.3% to $2.37
- Closed at $2.37, +1.28% vs the prior close of $2.34. Day range $2.27–$2.44, opened at $2.42.
- Volume was 1.74M shares, 1.1x its 50-day average of 1.58M.
- Price is -10.2% vs its 50-day average ($2.64) and +2.8% vs its 200-day average ($2.30).
- 52-week range $1.18–$3.11; today's close sits at 62% of that range, 23.7% below the 52-week high.
Oct 5, 2026 — OVID dips 1.7% to $2.34, a 1-month low, 4 down days in a row
- Closed at $2.34, -1.68% vs the prior close of $2.38. Day range $2.29–$2.47, opened at $2.38.
- Volume was 1.19M shares, 0.8x its 50-day average of 1.57M.
- Price is -11.3% vs its 50-day average ($2.64) and +1.7% vs its 200-day average ($2.30).
- 52-week range $1.18–$3.11; today's close sits at 60% of that range, 24.6% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — OVID dips 2.1% to $2.38, a 1-month low, 3 down days in a row
- Closed at $2.38, -2.06% vs the prior close of $2.43. Day range $2.33–$2.48, opened at $2.47.
- Volume was 2.17M shares, 1.3x its 50-day average of 1.62M.
- Price is -9.8% vs its 50-day average ($2.64) and +3.7% vs its 200-day average ($2.30).
- 52-week range $1.18–$3.11; today's close sits at 62% of that range, 23.3% below the 52-week high.
- That makes 3 straight losses.
OVID latest news & SEC filings
Every SEC filing by or about OVID in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 24, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $733.00K (prior year $6.27M) (-88.3% vs Jun 30, 2025)
- Net income: -$15.01M (prior year -$4.68M) (loss widened vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Exhibits / financial statements only (Item 9.01).
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 8, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade OVID
- Last results release: Mar 18, 2026 (8-K Item 2.02). Previous ones: Nov 12, 2025, May 13, 2025, Mar 11, 2025. Based on that rhythm, the next report is likely around Jun 17, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.85% (largest 9.1%).
- Liquidity: about 1.58M shares (≈$3.39M) trade per day on average.
- 52-week position: $2.15 vs a range of $1.18–$3.11 (50% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 8 sales; latest: Jeffrey A Rona sold 8,541 shares on Feb 23, 2026.
- Latest filings: 10-Q Aug 13, 2026; 8-K Aug 13, 2026; 8-K Jul 8, 2026.
- Share count: 195.30M shares outstanding (Aug 11, 2026), +174.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
OVID market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.26 | 2.30 | 2.11 | 2.15 | 1.33M |
| Oct 15, 2026 | 2.21 | 2.31 | 2.19 | 2.26 | 1.33M |
| Oct 14, 2026 | 2.18 | 2.26 | 2.09 | 2.19 | 1.64M |
| Oct 13, 2026 | 2.41 | 2.41 | 2.18 | 2.19 | 1.64M |
| Oct 12, 2026 | 2.45 | 2.49 | 2.39 | 2.41 | 876.00K |
| Oct 9, 2026 | 2.37 | 2.47 | 2.33 | 2.46 | 1.41M |
| Oct 8, 2026 | 2.32 | 2.36 | 2.29 | 2.34 | 1.65M |
| Oct 7, 2026 | 2.36 | 2.46 | 2.34 | 2.36 | 1.00M |
| Oct 6, 2026 | 2.42 | 2.44 | 2.27 | 2.37 | 1.74M |
| Oct 5, 2026 | 2.38 | 2.47 | 2.29 | 2.34 | 1.19M |
| Oct 2, 2026 | 2.47 | 2.48 | 2.33 | 2.38 | 2.17M |
| Oct 1, 2026 | 2.49 | 2.53 | 2.42 | 2.43 | 1.35M |
| Sep 30, 2026 | 2.54 | 2.61 | 2.48 | 2.49 | 1.44M |
| Sep 29, 2026 | 2.47 | 2.54 | 2.42 | 2.54 | 1.16M |
| Sep 28, 2026 | 2.40 | 2.49 | 2.35 | 2.46 | 1.19M |
| Sep 25, 2026 | 2.49 | 2.51 | 2.40 | 2.40 | 1.36M |
| Sep 24, 2026 | 2.54 | 2.54 | 2.40 | 2.49 | 1.53M |
| Sep 23, 2026 | 2.75 | 2.75 | 2.44 | 2.57 | 2.64M |
| Sep 22, 2026 | 2.76 | 2.85 | 2.71 | 2.76 | 3.74M |
| Sep 21, 2026 | 2.73 | 2.76 | 2.65 | 2.71 | 1.18M |
About Ovid Therapeutics
Ovid Therapeutics (OVID) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1636651.
OVID board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Margaret A. Alexander | President and CEO | Mar 2, 2026 |
| Karen Bernstein | Director | Mar 2, 2026 |
| Barbara Gayle Duncan | Director | Mar 2, 2026 |
| Kevin Joseph Fitzgerald | Director | Apr 9, 2026 |
| Bart Friedman | Director | Apr 9, 2026 |
| Anna Greka | Director | Jun 17, 2026 |
| Jeremy M Levin | Executive Chairman | Mar 25, 2026 |
| Stelios Papadopoulos | Director | Apr 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Margaret A. Alexander | President and CEO | Mar 2, 2026 |
| Charles Ross Carter | Chief Financial Officer | Jul 8, 2026 |
| Jeremy M Levin | Executive Chairman | Mar 25, 2026 |
| Jeffrey A Rona | CBFO | Mar 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Feb 23, 2026 | Jeffrey A Rona | Sale | 8,541 | $1.45 |
| Feb 23, 2026 | Jeffrey A Rona | Sale | 8,541 | $1.45 |
| Feb 23, 2026 | Jeffrey A Rona | Sale | 8,541 | $1.45 |
| Feb 23, 2026 | Jeffrey A Rona | Sale | 8,541 | $1.45 |
| Feb 23, 2026 | Margaret A. Alexander | Sale | 11,656 | $1.45 |
| Feb 23, 2026 | Margaret A. Alexander | Sale | 11,656 | $1.45 |
| Feb 23, 2026 | Margaret A. Alexander | Sale | 11,656 | $1.45 |
| Feb 23, 2026 | Margaret A. Alexander | Sale | 11,656 | $1.45 |
OVID financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $7.25M | $-17.41M | — | $-38.33M |
| Dec 31, 2024 | $566.00K | $-26.43M | — | $-55.96M |
| Dec 31, 2023 | $392.00K | $-52.34M | -0.74 | $-45.78M |
| Dec 31, 2022 | $1.50M | $-54.17M | -0.77 | $-55.23M |
| Dec 31, 2021 | $208.38M | $122.83M | 1.76 | $118.61M |
Latest balance sheet: total assets $231.97M, total liabilities $22.08M, cash $11.33M (as of Jun 30, 2026).
OVID earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Mar 18, 2026 | 8-K Item 2.02 (results) | $2.30 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.32 |
| May 13, 2025 | 8-K Item 2.02 (results) | $0.29 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $0.49 |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 8, 2024 | 8-K Item 2.02 (results) | — |
| Nov 3, 2023 | 8-K Item 2.02 (results) | — |
| Aug 4, 2023 | 8-K Item 2.02 (results) | — |
| May 5, 2023 | 8-K Item 2.02 (results) | — |
| Mar 13, 2023 | 8-K Item 2.02 (results) | — |
| Nov 8, 2022 | 8-K Item 2.02 (results) | — |
| Aug 9, 2022 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on OVID
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.